Comments on: The push and pull of third world drugs http://www.sciencebase.com/science-blog/the-push-and-pull-of-third-world-drugs.html Science Blog from Freelance Science Writer David Bradley Thu, 09 Feb 2012 08:25:37 +0000 hourly 1 http://wordpress.org/?v=3.3.1 By: Singemonkey http://www.sciencebase.com/science-blog/the-push-and-pull-of-third-world-drugs.html/comment-page-1#comment-637137 Singemonkey Tue, 22 Jun 2010 09:44:51 +0000 http://www.sciencebase.com/science-blog/?p=5724#comment-637137 It seems to me that governments of developing countries should be pouring more money into this research, and the purchase of drugs derived from increased research into NTDs and the like. It is their economies that really stand to gain from the release from the depressive effect of these epidemics. Consortia should be formed by most effected nations to fund R&D - in addition to any other measures. It seems to me that governments of developing countries should be pouring more money into this research, and the purchase of drugs derived from increased research into NTDs and the like.

It is their economies that really stand to gain from the release from the depressive effect of these epidemics. Consortia should be formed by most effected nations to fund R&D – in addition to any other measures.

]]> By: Andrew Sun http://www.sciencebase.com/science-blog/the-push-and-pull-of-third-world-drugs.html/comment-page-1#comment-637126 Andrew Sun Sat, 19 Jun 2010 09:36:50 +0000 http://www.sciencebase.com/science-blog/?p=5724#comment-637126 I think it is still hard to overcome the low-return problem of Third-World drug business, compared with the so-call Type I drugs. When it comes to patients we are talking about a portion of the population of more than one countries who definitely will buy the drug. For Type I drugs it is big profit but for Type III it is big loss. If it is the low return (i.e. price at which people will buy is lower than what businessmen will do) that hinders the progress, the money gap between is huger than any government can fill. Of course I only sat before the computer and guess the above things. I would like know how I am wrong. But I think it is normal to see a gradient in general global effort from Type III to Type I. It is hard to make them seem equal. I think it is still hard to overcome the low-return problem of Third-World drug business, compared with the so-call Type I drugs. When it comes to patients we are talking about a portion of the population of more than one countries who definitely will buy the drug. For Type I drugs it is big profit but for Type III it is big loss. If it is the low return (i.e. price at which people will buy is lower than what businessmen will do) that hinders the progress, the money gap between is huger than any government can fill.

Of course I only sat before the computer and guess the above things. I would like know how I am wrong. But I think it is normal to see a gradient in general global effort from Type III to Type I. It is hard to make them seem equal.

]]>